Next Article in Journal
Molecular Characterization of Major Structural Protein Genes of Avian Coronavirus Infectious Bronchitis Virus Isolates in Southern China
Next Article in Special Issue
West Nile Virus in the United States — A Historical Perspective
Previous Article in Journal
Lessons in AIDS Vaccine Development Learned from Studies of Equine Infectious, Anemia Virus Infection and Immunity
Previous Article in Special Issue
West Nile Virus State of the Art Report of MALWEST Project
Article Menu

Export Article

Open AccessReview
Viruses 2013, 5(12), 2977-3006;

West Nile Virus Drug Discovery

Novartis Institute for Tropical Diseases, 10 Biopolis Road, Chromos 05-01, Singapore 138670, Singapore
Author to whom correspondence should be addressed.
Received: 3 October 2013 / Revised: 25 November 2013 / Accepted: 25 November 2013 / Published: 3 December 2013
(This article belongs to the Special Issue West Nile Virus)
Full-Text   |   PDF [932 KB, uploaded 12 May 2015]   |  


The outbreak of West Nile virus (WNV) in 1999 in the USA, and its continued spread throughout the Americas, parts of Europe, the Middle East and Africa, underscored the need for WNV antiviral development. Here, we review the current status of WNV drug discovery. A number of approaches have been used to search for inhibitors of WNV, including viral infection-based screening, enzyme-based screening, structure-based virtual screening, structure-based rationale design, and antibody-based therapy. These efforts have yielded inhibitors of viral or cellular factors that are critical for viral replication. For small molecule inhibitors, no promising preclinical candidate has been developed; most of the inhibitors could not even be advanced to the stage of hit-to-lead optimization due to their poor drug-like properties. However, several inhibitors developed for related members of the family Flaviviridae, such as dengue virus and hepatitis C virus, exhibited cross-inhibition of WNV, suggesting the possibility to re-purpose these antivirals for WNV treatment. Most promisingly, therapeutic antibodies have shown excellent efficacy in mouse model; one of such antibodies has been advanced into clinical trial. The knowledge accumulated during the past fifteen years has provided better rationale for the ongoing WNV and other flavivirus antiviral development. View Full-Text
Keywords: drug discovery; antiviral; West Nile virus; flavivirus drug discovery; antiviral; West Nile virus; flavivirus

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Lim, S.P.; Shi, P.-Y. West Nile Virus Drug Discovery. Viruses 2013, 5, 2977-3006.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top